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Abstract This consensus position represents the collective
views of 35 gynaecologists with a recognised interest in
adhesions. The first part of the position was presented in the
previous issue of Gynecological Surgery and reviewed the
published literature on the extent of the problem of
adhesions. In this part, the opportunities to reduce their
incidence are considered. Collective proposals on the
actions that European gynaecologists should take to avoid
causing adhesions are provided. Importantly, in this part,
the need to now inform patients of the risks associated with
adhesion-related complications during the consent process
is discussed. With evidence increasing to support the
efficacy of adhesion-reduction agents to complement good
surgical practice, all surgeons should act now to reduce
adhesions and fulfil their duty of care to patients.
Keywords Adhesions . Adhesiolysis . Guidelines .
Gynaecology . Surgery
Introduction
Adhesions are the most frequent complication of abdominal
surgery and may represent one of the greatest unresolved
medical problems in medicine today [1], yet, many
surgeons are still not aware of the extent of the problem
and its serious consequences.
Recent epidemiological data have demonstrated that,
despite advances in surgical techniques in recent years, the
burden of adhesion-related complications has not changed
[2, 3]. While laparoscopic procedures are commonly
believed to be less adhesiogenic and cause fewer de novo
adhesions to form compared to open surgery [4, 5], for
many procedures, the comparative risk of adhesion-related
complications following open and laparoscopic gynaeco-
logical surgery is similar [3].
Developments in adhesion-reduction strategies and new
agents do, however, now offer a realistic possibility of
reducing the risk of adhesions forming and, thus, may
improve the outcomes for patients and the associated
onward burden. The importance of providing clear recom-
mendations on adhesions and their prevention following
gynaecological surgery is very apparent.
The paper details the second part of the project
undertaken by the Expert Adhesions Working Party of the
European Society of Gynaecological Endoscopy (ESGE).
The first paper published in the previous issue of
Gynecological Surgery provided an overview of the
published literature on the extent of the problem of
adhesions and, in this paper, the opportunities to reduce it
are presented. A consensus of opinion on the actions that
European gynaecologists should now take is provided.
These proposals are collective opinions and should not be
used for performance measures or competency purposes.
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Together, these two papers provide a collective consensus
position which it is hoped will raise the level of awareness
and the understanding of adhesions, and the associated
healthcare burden and costs, thereby, encouraging heightened
discussions and actions to address this area of unmet need.
Steps to reduce adhesions
The generally accepted method of reducing adhesions is a
meticulous surgical technique [6] and, within that, the rules of
microsurgery are fundamental [7]. In particular, they need to
be re-emphasised in laparoscopic surgery and in the treatment
of endometriosis, where there is heightened inflammatory
response and angiogenesis, with a corresponding propensity
for adhesion development [7] (Table 1).
Many of the traumas that cause adhesions are a routine part
of surgery and, even if adhesion-reduction strategies are
adopted, there can be conflicts—meticulous haemostasis is
very important but, to achieve this, limiting the use of cautery
may be problematic. Therefore, even if meticulous and careful
surgical technique is employed, postoperative adhesions are
very common [8]. Any type of surgery (however experienced
the surgeon) at any site can cause postoperative adhesions
and, while surgeons should adopt the adhesion reduction
steps as listed in Table 1 during all operations, these steps
may not be sufficient to prevent adhesion formation, as
evidenced by the SCAR study data [2, 3].
Importantly, while surgical adhesiolysis is the current
method of managing adhesions, regardless of the method of
adhesiolysis or the type of adhesion, it results in further
traumatic disruption and a high rate of adhesion reforma-
tion (mean 85%), as well as the development of de novo
adhesions [9]. Studies indicate that, compared with unaf-
fected peritoneal tissue, adhesive tissue contains higher
levels of growth factors, suggesting a greater propensity for
adhesion reformation. These factors (fibroblast growth
factor) depress fibrinolytic activity and induce tissue
fibrosis and, thus, reformed adhesions tend to be more
dense and severe than de novo adhesions [10, 11].
Adhesion-reduction agents
A number of adjuvants and strategies have been investigat-
ed, including both pharmacological agents and physical
barriers. Decisions on which agent to use are made by the
individual surgeon but there is a clear place for agents that
are safe, simple to use, clinically effective and affordable.
The quality of research on the use of adhesion-reduction
agents is, unfortunately, variable. Most studies have looked
at reduction in adhesions as the endpoint. In the majority of
cases, the studies have compared the use of an agent with
no treatment, sometimes in the same patient. Few studies
have been blinded, with most evaluations of adhesion
reduction made by the operating surgeon. The variation in
adhesion classifications, mode of application of agents, lack
of uniformity in surgical approaches and variations in the
interpretation of results all make the assessment of the
efficacy of the many agents difficult and almost impossible
to compare. There are very few studies that have looked at
the impact of an agent on clinical outcomes, such as
pregnancy, reduction in SBO or ease of reoperative surgery.
This is largely because of the complexity of undertaking
clinical outcome studies in surgery [12]. Looking at
pregnancy as an outcome in women with infertility, which
is multi-factorial, is problematic. Likewise, the number of
patients needed to power a study to show a reduction in
SBO is considerable [12], requiring many centres or a
lengthy time period to undertake such work, which can lead
to bias with inter-centre and inter-surgeon variables and
changes in surgical practice [13]. To date, studies required
for regulatory approvals of adhesion-reduction agents have
focussed on adhesion reduction [14].
Pharmacological agents
The processes of adhesion formation present various
theoretical opportunities for pharmacological intervention.
A number of agents have been investigated, including
antibiotics, NSAIDs, corticosteroids and fibrinolytics [15,
16]. To date, no clinical studies have shown adhesion-
reduction benefits using pharmacological regimens [17] and
there are safety concerns with some agents [18, 19].
Theoretically, drugs may be limited by their inability to
Table 1 Adhesion-reduction steps
Carefully handle tissue with field enhancement (magnification)
techniques
Focus on planned surgery and, if any secondary pathology is
identified, question the risk benefit of surgical treatment before
proceeding
Perform diligent haemostasis but ensure diligent use of cautery
Reduce cautery time and frequency and aspirate aerosolised tissue
following cautery
Excise tissue—reduce fulguration
Reduce duration of surgery
Reduce pressure and duration of pneumoperitoneum in laparoscopic
surgery
Reduce risk of infection
Reduce drying of tissues (limit heat and light)
Use frequent irrigation and aspiration in laparoscopic and laparotomic
surgery
Limit use of sutures and choose fine non-reactive sutures
Avoid foreign bodies—such as materials with loose fibres
Minimal use of dry towels or sponges in laparotomy
Use starch- and latex-free gloves in laparotomy
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reach the site and to stay there long enough to be effective
[19], since surgical sites are often poorly vascularised, as
are most injury sites. Rapid resorption through the
peritoneal membrane occurs with small molecules, thus,
removing many agents delivered intraperitoneally. More-
over, many processes involved in adhesion formation are
also part of normal wound healing, so any pharmacological
agent needs to reduce fibrin deposition, yet still allow for
re-epithelialisation.
Research continues on a range of pharmacological agents
but they are still at an experimental stage and the practical
use of such agents in routine surgery is some way off.
Physical separators
Barriers are currently the only available adjuncts to reduce
adhesion formation. The key requirement of any barrier is
that it should effectively separate traumatised peritoneal
surfaces during the critical period of adhesion development
in the 3–5 days after surgery, during which, peritoneal
healing occurs [20].
This separation can broadly be achieved by use of site-
specific mechanical barriers (films and gels) or by the use
of broad-coverage fluid agents to keep tissue surfaces
physically separated during the healing process.
The available agents are summarised in Table 2 and
outlined in the following sections.
Site-specific mechanical barriers
These have been used for some time, initially in the form of
omental or peritoneal grafting. More recently, inert barriers have
been introduced to be used at the site of trauma; for example,
over a suture line for procedures such as myomectomy.
Table 2 Overview of the available anti-adhesion agents
Agent Approval Safety Limitations Clinical studies Cost
Europe* US FDA
Site-specific
Preclude ✓ ✓ Tissue
separation
✓ Suture in place Limited €€
Interceed ✓ ✓ Open ✓ Incompatible with blood Many studies €€
Remove irrigants before use
Handling
- One limited pregnancy
outcomes study
Seprafilm ✓ ✓ Open ✓ But
anastomosis
Remove irrigants before use A number of studies €€(€)
Handling - Laparotomy only
Difficult to apply in
laparoscopy
- SBO study - limited results
SprayGel ✓ No ? Complex and capital
equipment needed
Very limited €€€
- Pivotal study halted
Hyalobarrier
gel
✓ No ✓ Handling Limited €(€)
No irrigation after application - One limited pregnancy
outcomes study
SurgiWrap ✓ No ? Peritoneal replacement film None €€(€)





✓ No ✓ Availability Very limited ??
- Pilot studies only
Broad coverage
Adept ✓ ✓ Lap ✓ Clinical studies in laparoscopy
only
Limited €
- Double blind study
- Active control
* At least one country
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Preclude® (Gore-tex—expanded polytetrafluoroethylene,
PTFE)
One of the first physical membranes used was Preclude®. It
has to be sutured in place and is not resorbable, so it has to
be removed at a second laparoscopy, which substantially
limits its applicability in peritoneal surgery. Preclude® is
rarely used in Europe and resorbable barriers have
subsequently been introduced which have greater clinical
utility.
Interceed® (oxidised regenerated cellulose)
The first resorbable membrane was Interceed®, first
introduced in 1990. It forms a viscous gel when it comes
into contact with fluids and is completely resorbed after
4 weeks. It can be used at most intraperitoneal locations and
in laparoscopic as well as open surgery—although laparo-
scopic application is challenging [21]. Meticulous haemo-
stasis is important, as the efficacy of the product is reduced
in the presence of blood [22, 23]. There is substantial
literature on the use of Interceed® in gynaecological
surgery and the product has been shown to reduce adhesion
formation without affecting wound healing [24–31]. How-
ever, the quality of many of the studies is limited by study
design, with surgery only as the control. Although a
systematic review of the literature in 1999 concluded that
no study reported pregnancy or the reduction of pain as an
outcome [25], more recent work with Interceed® indicated
that its effect on reducing adhesions results in improved
pregnancy outcomes in infertile patients [29]. While the
number of patients in this study was limited, the use of
Interceed® resulted in a significant increase in the preg-
nancy rate compared to surgical controls. These results are
very important for all anti-adhesion agents, as they show
that adhesion reduction using an anti-adhesion agent is a
valid endpoint.
Seprafilm® (hyaluronic acid/carboxymethylcellulose)
Seprafilm® is another barrier film [32, 33], which is usually
placed over a suture line. It persists during the period of re-
epithelialisation and is absorbed spontaneously. Seprafilm®
does not conform to the shape of the pelvic organs as well
as Interceed® and is usually used as a barrier placed
between the bowel or omentum and the anterior abdominal
wall at the time of wound closure, where it can prevent
adherence and, potentially, reduce the risk of enterotomy at
subsequent surgery. It is generally difficult to handle and its
use in laparoscopic surgery is not realistic. Alongside the
main pivotal studies [32, 33], there is mounting literature on
its use and it is the only agent to have been investigated for
the reduction of SBO [34, 35]. This study reported a
significant reduction in adhesive small bowel obstruction
requiring reoperation by the use of Seprafilm® (1.6%
absolute reduction) [35]. A mean of 4.5 sheets per patient
was used to effect adequate coverage, which is costly [34,
35]. While the study also provided confirmation of general
safety in colorectal surgery, it highlighted that the use of
Seprafilm® at the site of an anastomosis is to be avoided,
due to increased anastomotic leaks [34].
SurgiWrap® (polylactide: copolymer of 70:30 Poly
[L-lactide-co-D,L lactide])
SurgiWrap® is a biodegradable polymer film which has a
European device licence for the reduction of postoperative
adhesions following abdominal, pelvic, gynaecological or
cardiac surgery. The supplying company claims that the
product has improved handling over alternative film
products and a long resorption period of up to 6 months,
after which, it is subsequently metabolised to lactic acid,
CO2 and water. The polymer film needs to be sutured in
place to prevent it from moving during this period. With the
exception of one preclinical study in 44 rats [36], published
data are lacking on which to assess the product’s safety or
its efficacy in reducing peritoneal adhesions. In light of
failures of other agents due to long-term safety concerns
and in the absence of evidence of clinical efficacy, the use
of SurgiWrap® as an adhesion-reduction agent is not to be
encouraged at this time.
Gel barriers
A fundamental limitation of site-specific mechanical bar-
riers is the requirement of the surgeon to predict where
clinically significant adhesions are likely to form in order to
decide where to place the product. In addition, site-specific
barriers are difficult to use in laparoscopic surgery. As a
result of these limitations, gel barriers have also been
developed.
Hyalobarrier® (hyaluronic acid cross-linked
to hyaluronic acid)
Hyalobarrier® is a viscous gel, available in Europe as an
adhesion-reduction barrier for use after abdominopelvic
surgery. It is similar in mode of action to local site-specific
film barriers, as it stays at the site to which it is applied,
dissolving some days later. There are few published clinical
data: there is a small uncontrolled study in myomectomy by
laparotomy [37] and two randomised, controlled studies in
patients undergoing laparoscopic myomectomy [38, 39].
Although the studies only used limited numbers of patients,
they showed a reduction in adhesions and, in the smaller
study [38], the pregnancy rate in patients treated with
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Hyalobarrier® was significantly greater than in the control
group (surgical treatment only) [40] and similar to that seen
with Interceed® [29]. Hyalobarrier® is not widely available
nor has it been adopted for clinical use in surgery, mainly
because it is very sticky and has a tendency to float away
from sites when irrigated. These mucoadhesive properties
are essential for its efficacy and irrigation is not recom-
mended. However, it has been researched for use in
reducing intrauterine adhesions following hysteroscopic
surgery with success [41–43] and may be useful in this
situation.
SprayGel® (synthetic polyethylene glycol (PEG) solutions)
SprayGel® is a gel barrier coating system which was
approved for use in laparoscopic and open surgery in
Europe at the end of 2001. It consists of two water-based
PEG solutions, one clear and one coloured with methylene
blue, to make it easy to see where it has been used. When
sprayed together, these two solutions react with each other
at the target tissue, where they mix to form a hydrogel film
that provides a physical barrier. This barrier remains in
place for up to 7 days and is then absorbed and excreted
through the kidneys.
In preliminary clinical trials, the use of SprayGel®
resulted in a decrease in the incidence, severity and extent
of post-surgical adhesion formation [44, 45]. A larger scale
pivotal study had commenced in the USA but was then
stopped due to lack of efficacy in the treatment compared to
the control arm and has not, to date, been resumed.
The use of SprayGel® is limited by the complex setting
up of the equipment and the skill and time required to spray
and coat tissues evenly. It is also expensive. If there is
extensive operative surgery in the pelvis as well as
abdominal adhesiolysis, it may be necessary to use two
kits and as many as five kits to effect adequate coverage of
the complete peritoneal wound area [46].
Oxiplex®/AP (carboxymethylcellulose (CMC)
and polyethylene oxide (PEO) composite gel)
Most recently, Oxiplex®/AP, a viscoelastic gel, has been
approved for use in Europe as an adhesion-reduction
barrier for abdominal/pelvic surgery. It has been used in
another formulation for a number of years for the
reduction of adhesions in spinal surgery [47]. Two clinical
pilot studies in laparoscopic gynaecological surgery com-
paring use of this gel with no treatment have recently been
published [48, 49]. They are primarily safety studies and
are, thus, empowered to assess the safety and not the
efficacy of the agent. However, in both studies, there was
an improvement in the American Fertility Society (AFS)
scores compared to the no-treatment controls and the
European pilot study demonstrated a significant reduction
in adnexal adhesions [48].
These gel agents, like the film barriers, are site-specific,
requiring surgeons to predict sites at which adhesions may
form and, thus, where the film barrier needs to be applied.
However, the pathogenesis of adhesion formation reaches
beyond the operative site of actual surgical trauma. The
effects of ischaemia, heat, drying, handling and contami-
nation mean that agents providing protection throughout the
peritoneal cavity could be advantageous.
Broad-coverage fluid agents
Various broad-coverage agents have been developed but
most have been abandoned (Hyskon® [50]) or withdrawn
due to safety issues (Intergel® [51]) or the lack of efficacy
(Hyskon® [52], Sepracoat®).
Hydroflotation has long been suggested as a technique
that may be efficacious, both at the site of application and
elsewhere in the pelvis. It involves the instillation of a fluid
into the peritoneal cavity at the end of the procedure to
provide a physical fluid barrier, preventing the apposition
of damaged peritoneal surfaces. Saline, lactated Ringer’s
solution or Hartmann’s solution have all been used widely.
However, these crystalloid solutions are absorbed rapidly
and do not reduce adhesions [53]. They are absorbed from
the peritoneal cavity at the rate of 30–50 ml per hour, so
that, by 24 hours after surgery, little, if any, solution is left
in the pelvis [54–56]. Studies have also shown that some
irrigants, including lactated Ringer’s solution, can have
deleterious effects on the delicate mesothelial lining of the
peritoneum [57, 58].
Adept® (4% icodextrin solution)
Adept® is the single approved and available adhesion-
reduction solution that has a sufficiently long intraperito-
neal residence [59] to provide coverage throughout the
peritoneal cavity and persist through the critical period of
adhesion formation [20]. Adept® has been approved in
Europe since 2000 as an adhesion-reduction agent in
open and laparoscopic gynaecological and general sur-
gery. In the USA, it was recently approved by the FDA
for use as an irrigant and post-operative instillate in
gynaecological laparoscopy with adhesiolysis. It is the
first anti-adhesion agent to be granted such approval.
Adept® is a non-viscous, iso-osmotic, clear solution
which handles like normal saline, requires no change to
surgical practice or any special training. It does not
potentiate infection [60] and no differences have been
demonstrated between Adept® and lactated Ringer’s solu-
tion (LRS) in the healing and strength of midline incisions
and bowel anastomoses [61].
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Early work with Adept® as an anti-adhesion agent
showed that it is best used throughout surgery as an irrigant
fluid to reduce dessication and following surgery as an
instillate (1000 mL) [60, 62]; all work with Adept® has
used this combined approach.
Initial clinical studies were encouraging [62] and,
recently, efficacy has been further established in a pivotal
randomised USA multi-centre study in gynaecological
laparoscopy [63]. This study is the largest and the first
double-blind study of an anti-adhesion agent. As well as
confirming the safety of Adept®, the data demonstrate a
significant reduction in adhesions throughout the peritoneal
cavity when Adept® is used as an irrigant and post-
operative instillate.
A European patient registry (ARIEL) for Adept® use
was established alongside the formal clinical trial
programme, providing surgeons’ feedback on the use and
safety of Adept® in routine open and laparoscopic
gynaecological [64] and general surgery [65] in 4,620
patients—2,882 of whom underwent gynaecological sur-
gery (2,069 laparoscopy, 813 laparotomy). The study
showed that, in routine use, Adept® is well tolerated by
patients, is easy to use and has a good safety profile.
Areas of future research
Laparoscopic pneumoperitoneum
While it is widely considered that laparoscopy may be less
adhesiogenic than laparotomy, there are some inconsisten-
cies when epidemiological data on adhesion-related out-
comes are considered [3]. Since laparoscopy is minimally
invasive and, thus, associated with less surgical trauma than
laparotomy, there is rising concern that the CO2 pneumo-
peritoneum may be an important adhesiogenic factor. This
may be due to the CO2 inducing local changes such as
intraperitoneal acidosis [66–68] or, in the absence of
moistening, dessication of the mesothelium [69]. The
intraperitoneal pressure associated with prolonged pneumo-
peritoneum may also induce adverse effects on the
microcirculation [70, 71], possibly inducing hypoxaemia
[72]. This hypoxia, together with other mesothelial insult,
may stimulate the expression of factors such as vascular
endothelial growth factor (VEGF), resulting in an increase
in adhesion formation [72]. As a result of this animal work,
active research for other potential adhesion-reduction
strategies involving insufflators has begun [73, 74].
Cost-effectiveness of anti-adhesion agents
Post-operative adhesions clearly have an important impact
on the successful clinical outcome of surgery and pose an
important cost burden. In considering the use of an
adhesion-reduction agent, factors to be taken into consid-
eration include not only its safety, ease of use and clinical
efficacy, but also whether it is cost-effective. While it is
difficult to evaluate the impact that an anti-adhesion agent
will have on subsequent clinical outcomes and, thus,
whether it will be cost-effective [12], it is possible to
model this.
Epidemiological data from the SCAR study [75] have
been used to model the cumulative costs over time of
adhesion-related hospital readmissions following surgery
with or without the use of an adhesion-reduction agent [12]
and have recently been updated with the costs of inflation.
This model is helpful in understanding the value of
different adhesion-reduction agents and suggests that a
suitably priced and effective agent can result in overall cost
savings to a healthcare system. For example, agents costing
around €130 only need to demonstrate a 26% reduction in
adhesion-related readmissions 3 years after surgery to
return their costs, whereas agents costing around €300 per
operation would need to demonstrate at least a 60%
reduction in adhesion-related readmissions 3 years after
surgery to return the costs of their investment (Fig. 1) [12].
Fig. 1 Cumulative costs of adhesion-related readmissions for 100
patients, following surgery with or without an adhesion-reduction
agent. Modelled on the efficacy required to pay back the cost of
treatment after 3 years [12] for €130 and €300 agent costs
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In either scenario, extension of the model assessment period
beyond 3 years after surgery results in cost savings.
It is clear from this that, in considering the choice of an
adhesion-reduction agent, the cost as well as the clinical
impact of the agent needs to be considered carefully. This is
particularly the case if the prophylactic use of adhesion-
reduction agents is to be adopted widely in routine surgery.
Advising patients and medicolegal considerations
Even with advances in surgical techniques, it is clear that
adhesions remain a common consequence of surgery, with
serious health implications for patients, including SBO,
infertility and chronic pelvic pain. Even if adhesions are
“silent,” posing no apparent issues for the patient, the risks
of complications at reoperative surgery and late SBO onset
are considerable.
Adhesion-related complications are increasingly becom-
ing the subject of forensic and medicolegal debate and there
is evidence that medicolegal litigation resulting from
complications secondary to postoperative adhesion forma-
tion are adding to the healthcare costs and the clinician’s
burden [76, 77].
In the consent process, it is recommended that patients
should be advised of the reasons for and nature of the
procedure, the benefits, risks, discomforts and alternatives
and the consequences of not undergoing the procedure.
It is common practice in the consent process to advise
patients of risks of complications, such as general anaes-
thesia (<1:100), and general complications after laparo-
scopic surgery, e.g. pain, bleeding, infection, damage to the
bowel/bladder/urethra (1:1000 in sterilisations and 1:500
for other procedures) [78]. These risk ratios are less than
the risk of a directly adhesion-related readmission (adhe-
siolysis) in the first year after surgery following a known
high-risk laparoscopic procedure, such as an ovarian or
tubal procedure, or open ovarian surgery (1:80 following
laparoscopic surgery and 1:50 following open surgery).
Even in patients undergoing other therapeutic laparoscopic
surgery (excepting tubal sterilisations), the risk of a directly
adhesion-related readmission is 1:70 and, for open surgery
on the Fallopian tubes or uterus, it is 1:120 and 1:170,
respectively, i.e. comparatively high [3].
The International Adhesions Society undertook a survey
to review the information on adhesions that patients
received [79, 80]. In only 10.4% of cases were adhesions
mentioned as part of the informed consent process and in
14.4% adhesions were discussed but were not part of the
consent process. In patients undergoing specific adhesiol-
ysis surgery, 54% reported being given some kind of
information about adhesions but only 46% were given
information on adhesion-reduction agents. In procedures
not involving adhesiolysis, only 10% of patients reported
receiving any adhesion information and only 6% were
given information on adhesion-reduction agents.
Tissue damage to underlying structures during laparo-
scopic surgery has been shown to be the most common
cause of successful surgical negligence suits [81] and it is
estimated that the risk of bowel injury is between 10% and
25% of laparoscopic adhesiolysis cases [82] and there is a
19% risk of inadvertent enterotomy during reoperative
laparotomy [83]. Furthermore, in a study of misadventure
data following laparoscopic surgery, while injury to the
common bile duct was the most frequent problem,
perforation of the small bowel or colon was the second
most common injury and two-thirds of injuries were not
noted until after the end of the surgical procedure [84]. Risk
of damage was greater when there were difficulties visual-
ising structures—which can be a common issue when
operating on a patient with pre-existing adhesions.
With published evidence suggesting that the long-term
risk of adhesion-related complications is high in the
majority of gynaecological procedures, there is an urgent
need for gynaecologists to be cognisant of the potential for
medicolegal action [76, 77, 85] if patients are not informed
routinely of the risk of adhesions.
Consensus on how to avoid adhesions
To reduce the risk of adhesions, surgeons should actively
consider adopting anti-adhesion strategies as described
in Table 1, particularly in “high-risk” gynaecological
procedures (whether open or laparoscopic), such as
ovarian, endometriosis or tubal surgery, myomectomy and
adhesiolysis.
New developments in anti-adhesion products and our
practical knowledge of using such agents has increased in
recent years. Not all agents are difficult or costly to use and
there is now promising evidence of efficacy, not only in the
reduction of adhesions, but also in subsequent outcomes,
such as reduction in SBO or improvement in pregnancy
rates in infertile women.
At present, surgeons largely employ good surgical
practice to prevent adhesion formation and adhesiolysis to
treat adhesions—despite the high reformation rate [9].
Sound epidemiological studies have shown that, even with
advances in surgical practice, adhesions continue to
represent a significant burden for patients, surgeons and
healthcare systems. Evidence is increasing to support the
efficacy of adhesion-reduction agents to complement good
surgical practice, including agents that are relatively
inexpensive and simple to use (Table 2).
It is also time to advise our patients of the risks
associated with adhesion-related complications during the
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consent process. Failure to inform patients adequately of
the risks could, indeed, result in claims of medical
negligence.
Further research on the use of adhesion-reduction agents
is essential to better understand their impact on clinical
outcomes, recognising that such studies are difficult to
undertake [12]. Research also needs to continue into the use
of more effective adhesion-preventative agents and combi-
nations of strategies and agents. All surgeons should act
now to reduce adhesions, thereby, fulfilling their duty of
care to patients.
As the results of further studies on adhesions and
adhesion-reduction agents become available, the consensus
proposals below should be reviewed.
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Consensus proposals: actions to reduce adhesions
1. Adhesions need to be recognised as the most frequent
complication of abdominal surgery.
2. Surgeons, other healthcare workers, budget holders and
policy makers need to increase their awareness and
understanding of adhesions and the associated healthcare
burden and costs and take active steps to reduce this.
3. Patients need to be informed of the risk of adhesions, given
that adhesions are now the most frequent complication of
abdominal surgery.
4. Surgeons who do not advise of the risk of adhesions may
put themselves at risk of claims for medical negligence.
5. Surgeons have a duty of care to protect patients by
providing the best possible standards of care—which
should include taking steps to reduce adhesion formation.
6. Surgeons should adopt a routine adhesion-reduction strategy,






7. Good surgical technique is fundamental to any adhesion-
reduction strategy—see Table 1
8. Surgeons should consider the use of adhesion-reduction
agents as part of their adhesion-reduction strategy, giving
special consideration to agents with data to support safety
in routine abdominopelvic surgery and efficacy in
reducing adhesions. The practicality and ease of use of
agents, as well as the cost of any agent, will influence their
acceptability in routine practice.
9. Further research to understand the impact that adhesion-
reduction agents have on clinical outcomes will be
important.
10. Research towards more effective preventative agents
should be encouraged—including the use of combinations
of agents to prevent the formation of de novo adhesions,
as well as adhesion reformation.
11. Surgeons need to act now to reduce adhesions and fulfil
their duty of care to patients.
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